Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 May 31;12(1):51.
doi: 10.1186/s13048-019-0527-z.

Prognostic value of lymphocyte-to-monocyte ratio in ovarian cancer: a meta-analysis

Jun Gong  1 , Hui Jiang  2 , Chang Shu  1 , Mei-Qin Hu  1 , Yan Huang  3 , Qin Liu  4 , Rong-Feng Li  5   6
Affiliations
Review

Prognostic value of lymphocyte-to-monocyte ratio in ovarian cancer: a meta-analysis

Jun Gong et al. J Ovarian Res. .

Abstract

Introduction: Prognostic biomarkers are highly needed to properly manage patients with cancer and improve their clinical courses. The relationship between lymphocyte-to-monocyte ratio (LMR) at diagnosis and ovarian cancer prognosis has been extensively studied, but little consensus has been reached regarding its utility as a biomarker of poor outcome. Thus, this study aimed to investigate the potential prognostic value of pretreatment LMR in such patients to shed light on this issue.

Methods: We searched the scientific databases of MEDLINE, Embase, Cochrane Library, and WangFang for relevant studies about the inflammatory prognostic factor LMR in ovarian cancer, based on specific inclusion and exclusion criteria. The following parameters were analyzed among others: LMR values and respective cut-offs, patient's overall survival (OS) and progression-free survival (PFS), and clinicopathological features.

Results: Eight studies, including 2259 patients, were eligible for inclusion in this meta-analysis. We found that low LMR was associated with both poor OS [Hazard ratio (HR): 1.92; 95% confidence interval (CI): 1.58-2.34; p < 0.001] and PFS (HR: 1.70; 95% CI: 1.54-1.88; p < 0.001). Moreover, our findings revealed that low LMR was correlated with high G2/G3 histological grade (OR: 1.67; 95% CI: 1.26-2.20; p < 0.001) and late III-IV FIGO stage tumors (OR: 3.55; 95% CI: 2.68-4.70; p < 0.001), high serum CA-125 level (OR: 2.18; 95% CI: 1.71-2.77; p < 0.001), and presence of malignant ascites (OR: 1.87; 95% CI: 1.11-3.14; p = 0.02) and lymph node metastases (OR: 1.70; 95% CI: 1.13-2.54; p = 0.01).

Conclusion: Pretreatment LMR is a potential prognostic marker of poor outcome in ovarian cancer patients and may thus be important in clinical care and disease control.

Keywords: Lymphocyte-to-monocyte ratio; Meta-analysis; Ovarian cancer; Prognosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Flow diagram of study retrieval and selection processes
Fig. 2
Fig. 2
Pooled hazard ratio (HR) of lymphocyte-to-monocyte ratio (LMR) for overall survival (OS) in patients with ovarian cancer
Fig. 3
Fig. 3
Pooled hazard ratio (HR) of lymphocyte-to-monocyte (LMR) for progression-free survival (PFS) in patients with ovarian cancer
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Lim W, Song G. Discovery of prognostic factors for diagnosis and treatment of epithelial-derived ovarian cancer from laying hens. Journal of cancer prevention. 2013;18(3):209–220. doi: 10.15430/JCP.2013.18.3.209. - DOI - PMC - PubMed
    1. Hall TR, Dizon DS. Neoadjuvant chemotherapy for advanced epithelial ovarian cancer. Clin Adv Hematol Oncol. 2016;14(4):262–268. - PubMed
    1. Martin-Camean M, Delgado-Sanchez E, Pinera A, Diestro MD, De Santiago J, Zapardiel I. The role of surgery in advanced epithelial ovarian cancer. Ecancermedicalscience. 2016;10:666. - PMC - PubMed
    1. Mantia-Smaldone GM, Edwards RP, Vlad AM. Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies. Cancer Manag Res. 2011;3:25–38. - PMC - PubMed
    1. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–899. doi: 10.1016/j.cell.2010.01.025. - DOI - PMC - PubMed

Substances